leadf
logo-loader
viewSorrento Therapeutics

BioSig subsidiary ViralClear Pharmaceuticals to test its drug merimepodib in a combination coronavirus treatment

The deal will see Sorrento initiate testing with a selection of its agents in combination with ViralClear’s antiviral compound for possible synergistic effect against SARS-CoV-2 in a preclinical hamster model

Coronavirus graphic
If it goes well, the results could be presented to the Food and Drug Administration to support the initiation of a human clinical trial

BioSig Technologies Inc (NASDAQ:BGSM) subsidiary ViralClear Pharmaceuticals Inc announced an agreement with biopharmaceutical company Sorrento Therapeutics to test its coronavirus drug candidate merimepodib in combination with Sorrento’s neutralizing antibody candidate STI-1400.

The deal will see Sorrento initiate testing with a selection of its agents in combination with ViralClear’s antiviral compound for possible synergistic effect against SARS-CoV-2, the virus that causes COVID-19, in a preclinical hamster model. 

The study will look for synergy at the effective doses between the two drugs, which are separately each already in human clinical trials, and will try to specifically demonstrate that the combined benefits in strengthening and accelerating viral clearance exceed what each drug could deliver by itself, the company said.

READ: BioSig Technologies says subsidiary ViralClear Pharmaceuticals expanding drug development program to treat COVID-19

If it goes well, the results could be presented to the US Food and Drug Administration to support the initiation of a human clinical trial.

In general, multi-modal approaches are considered the most likely to succeed antiviral strategies, the company said. Even in the case of highly effective stand-alone therapies, a synergistic combination can be pursued to help reduce the effective dose needed of each individual agent and aim to ensure maximum effect.

Contact Andrew Kessel at [email protected]

Follow him on Twitter @andrew_kessel

Quick facts: Sorrento Therapeutics

Price: 6.94 USD

NASDAQ:SRNE
Market: NASDAQ
Market Cap: $1.82 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Purepoint Uranium Group sees great opportunity as they look to develop in...

Purepoint Uranium Group (CVE: PTU) President and CEO Chris Frostad joined Steve Darling from Proactive to shared details about the company that is focused on the exploration of its projects in the Canadian Athabasca Basin, the world’s richest uranium region. Frostad telling Proactive about...

8 hours, 56 minutes ago

2 min read